Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 1/20 | 0.47 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.45 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8763260 | 0.89 | ALDH1A1 (0.51) | GRIK1GRIK2CYP19A1CYP2C9CYP11B1 | |
| SCHEMBL8762887 | 0.89 | GRIK1 (0.59) | GRIK1GRIK2 | |
| SCHEMBL6118477 | 0.84 | NR4A1 (0.48) | GRIK1GRIK2 | |
| SCHEMBL8762994 | 0.83 | GRIK1 (0.47) | GRIK1GRIK2CYP2C9 | |
| SCHEMBL6118739 | 0.82 | TNIK (0.49) | GRIK1GRIK2TNIK | |
| SCHEMBL8762929 | 0.82 | CCR2 (0.45) | GRIK1GRIK2 | |
| SCHEMBL8763152 | 0.81 | CCR2 (0.44) | GRIK1GRIK2 | |
| SCHEMBL8762470 | 0.80 | — | — | |
| SCHEMBL8762189 | 0.79 | TSHR (0.59) | GRIK1GRIK2 | |
| SCHEMBL8763733 | 0.79 | CCR2 (0.44) | GRIK1GRIK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680120-B2 | Indole derivative or pharmaceutically acceptable salt thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2014-03-25 | — | — | US | disclosed |
| US-8680120-B2 | Indole derivative or pharmaceutically acceptable salt thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2014-03-25 | — | — | US | disclosed |
| US-20120129890-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-05-24 | — | — | US | disclosed |
| US-20120129890-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-05-24 | — | — | US | disclosed |
| WO-2011013624-A1 | INDOLE DERIVATIVE AND PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | キッセイ薬品工業株式会社 (JP) | 2011-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129890-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | PTGER1, CYSLTR1, ARRB1 | GRIK1 344/4885GRIK2 1244/4885CYP19A1 1214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.